Journal
BIOMOLECULES
Volume 13, Issue 3, Pages -Publisher
MDPI
DOI: 10.3390/biom13030403
Keywords
natural products; bergenin; biosynthesis; plants with bioavailability; pharmacological and biological activities
Categories
Ask authors/readers for more resources
Bergenin, a glycosidic derivative of trihydroxybenzoic acid, was first discovered in the rhizomes of Bergenia crassifolia. It has aroused interest due to its antioxidant and anti-inflammatory activities, as well as its potential in various other pharmacological activities. Bergenin is widely distributed in many plant species and its derivatives and extracts have been extensively studied, showing no cytotoxicity on healthy cells.
Bergenin is a glycosidic derivative of trihydroxybenzoic acid that was discovered in 1880 by Garreau and Machelart from the rhizomes of the medicinal plant Bergenia crassifolia (currently: Saxifraga crassifolia-Saxifragaceae), though was later isolated from several other plant sources. Since its first report, it has aroused interest because it has several pharmacological activities, mainly antioxidant and anti-inflammatory. In addition to this, bergenin has shown potential antimalarial, antileishmanial, trypanocidal, antiviral, antibacterial, antifungal, antinociceptive, antiarthritic, antiulcerogenic, antidiabetic/antiobesity, antiarrhythmic, anticancer, hepatoprotective, neuroprotective and cardioprotective activities. Thus, this review aimed to describe the sources of isolation of bergenin and its in vitro and in vivo biological and pharmacological activities. Bergenin is distributed in many plant species (at least 112 species belonging to 34 families). Both its derivatives (natural and semisynthetic) and extracts with phytochemical proof of its highest concentration are well studied, and none of the studies showed cytotoxicity for healthy cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available